PMID- 31108136
OWN - NLM
STAT- MEDLINE
DCOM- 20200406
LR  - 20200408
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 159
DP  - 2020 Jan
TI  - Series: Implications of the recent CVOTs in type 2 diabetes: Impact on 
      guidelines: The endocrinologist point of view.
PG  - 107726
LID - S0168-8227(19)30607-2 [pii]
LID - 10.1016/j.diabres.2019.05.005 [doi]
AB  - The management of type 2 diabetes mellitus (T2DM) essentially consists in 
      controlling hyperglycaemia, together with other vascular risk factors, in order 
      to reduce the incidence and severity of diabetic complications. Whereas glucose 
      control using classical glucose-lowering agents (except perhaps metformin) 
      largely fails to reduce cardiovascular disease (CVD), two new pharmacological 
      classes, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose 
      cotransporter type 2 inhibitors (SGLT2is), have proven their ability to reduce 
      major cardiovascular events in patients with established CVD. Furthermore, 
      SGLT2is reduced the risk of hospitalisation for heart failure and the progression 
      of renal disease. According to the 2018 ADA-EASD consensus report, the choice of 
      a second agent to be added to metformin should now be driven by the presence or 
      not of atherosclerotic CVD, heart failure or renal disease, all conditions that 
      should promote the use of a SGLT2i or a GLP-1 RA with proven efficacy. Thus 
      endocrinologists have to face a new paradigm in the management of T2DM, with a 
      shift from a primary objective of glucose control without inducing hypoglycaemia 
      and weight gain to a goal of cardiovascular and renal protection, largely 
      independent of glucose control. Of note, however, the latter remains crucial to 
      reduce the risk of microangiopathy.
CI  - Copyright (c) 2019. Published by Elsevier B.V.
FAU - Scheen, Andre J
AU  - Scheen AJ
AD  - Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, 
      CHU Liege, University of Liege, Liege, Belgium; Clinical Pharmacology Unit, CHU 
      Liege, Center for Interdisciplinary Research on Medicines (CIRM), University of 
      Liege, Liege, Belgium. Electronic address: andre.scheen@chuliege.be.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190518
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
SB  - IM
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Endocrinologists/*standards
MH  - Glucagon-Like Peptide-1 Receptor/*agonists
MH  - Guidelines as Topic
MH  - Heart Failure/*etiology
MH  - Humans
MH  - Renal Insufficiency, Chronic/*etiology
OTO - NOTNLM
OT  - Cardiovascular disease
OT  - Chronic kidney disease
OT  - GLP-1 receptor agonist
OT  - Guidelines
OT  - Heart failure
OT  - SGLT2 inhibitor
OT  - Type 2 diabetes
EDAT- 2019/05/21 06:00
MHDA- 2020/04/09 06:00
CRDT- 2019/05/21 06:00
PHST- 2019/05/02 00:00 [received]
PHST- 2019/05/08 00:00 [accepted]
PHST- 2019/05/21 06:00 [pubmed]
PHST- 2020/04/09 06:00 [medline]
PHST- 2019/05/21 06:00 [entrez]
AID - S0168-8227(19)30607-2 [pii]
AID - 10.1016/j.diabres.2019.05.005 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2020 Jan;159:107726. doi: 10.1016/j.diabres.2019.05.005. 
      Epub 2019 May 18.